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Randomised, double-blind, controlled trials are considered the gold standard for evaluating a pharmacological
agent, as they minimise any potential bias. However, it is not always possible to perform double-blind trials,
particularly for medications delivered via specific devices, e.g. inhalers. In such cases, open-label studies can be
employed instead. Methods used to minimise any potential bias introduced by open-label study design include
randomisation, crossover study design, and objective measurements of primary efficacy and safety variables.
Concise reviews analysing the effect of blinding procedures of comparator drugs on outcomes in respiratory trials
are limited. Here, we compare data from different chronic obstructive pulmonary disease trials with once-daily
indacaterol versus a blinded or non-blinded comparator. The clinical trial programme for indacaterol, a once-daily,
long-acting β2-agonist, used tiotropium as a comparator either in an open-label or blinded fashion. Data from these
studies showed that the effects of tiotropium were consistent for forced expiratory volume in 1 second, an
objective measure, across blinded and non-blinded studies. The data were consistent with previous studies of
double-blind tiotropium, suggesting that the open-label use of tiotropium did not introduce treatment bias. The
effect of tiotropium on subjective measures (St George’s Respiratory Questionnaire; transition dyspnoea index)
varied slightly across blinded and non-blinded studies, indicating that minimal bias was introduced by using open-
label tiotropium. Importantly, the studies used randomised, open-label tiotropium patients to treatment allocation, a
method shown to minimise bias to a greater degree than blinding. In conclusion, it is important when reporting a
clinical trial to be transparent about who was blinded and how the blinding was performed; if the design is open-
label, additional efforts must be made to minimise risk of bias. If these recommendations are followed, and the data
are considered in the full knowledge of any potential sources of bias, results with tiotropium suggest that data
from open-label studies can provide valuable and credible evidence of the effects of therapy.
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Randomised, controlled trials (RCTs) are considered the
gold standard for evaluating clinical interventions be-
cause of their ability to minimise bias [1]. Blinding is an
important technique to reduce bias in clinical trials [2,3].
However, it is not always possible to conduct such trials;
therefore, alternative study designs are often used.* Correspondence: k.beeh@insaf-wi.de
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reproduction in any medium, provided the orIn this review, we discuss the design of RCTs of
inhaled therapies in patients with chronic obstructive
pulmonary disease (COPD), with particular regard to the
use of blinding and open-label techniques. Data from
studies of two once-daily bronchodilators used in COPD,
indacaterol and tiotropium, will be used to evaluate the
potential for bias in open-label studies.Blinding in clinical trials
Administering treatment in a blinded manner is com-
plicated when comparing medications delivered viad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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it may be necessary to employ more complex methods,
such as double-dummy designs. Further difficulties may
arise due to the specific properties of some products
(e.g. a particular taste or sensation), which may make
their identity apparent during administration. The
presence of logos on branded products may also
present problems if it is not possible to obtain match-
ing placebos with identical branding or to obtain the
active drug in an unbranded form. If these difficulties
cannot be overcome, it may be necessary to use an
open-label design [5]. While double-blind trials are
considered as the gold standard for evaluating new
products, open-label studies may have some advan-
tages, such as simpler design, lower cost and closer re-
flection of everyday clinical practice [2,6,7].
In the design of open-label studies, great care is
needed to minimise possible sources of bias, which can
arise in several ways [3]. For example, patients who
know they are receiving an active drug, as opposed to
knowing they are on placebo, may report more
favourable outcomes because they expect a benefit. The
patient’s previous experience of a drug may also affect
their reporting of subjective efficacy endpoints or ad-
verse effects. Observers may also be biased by awareness
of treatment allocation, which might affect reporting of
treatment responses or adverse events. Knowledge of
treatment assignment could also affect decisions about
remaining on treatment or receiving concomitant medi-
cations or other therapy, as well as decisions about in-
clusion of results in an analysis.
Minimising bias in open-label studies
Strategies to minimise the likelihood of bias in open-
label studies include randomising patients after collec-
tion of baseline data [6] and use of crossover study
designs [2]. In a crossover design trial, each patient is
randomised to a sequence that includes each treatment;
hence, each patient can act as their own control for
treatment comparisons [2]. However, crossover designs
can be limited by the potential for carry-over effects
from the previous treatment and administration proced-
ure [2]. The design of crossover studies therefore needs
to incorporate appropriate wash-out and familiarisation
periods. Other means of minimising bias in open-label
studies include basing efficacy outcomes on objective
variables [6]. Spirometry is considered the most object-
ive, standardised and reproducible measure of airflow
limitation [8], and is therefore unlikely to be subject to
bias. Additionally, many clinical trials use a centralised
spirometry organisation to further reduce the possibility
of variability in the observation. Centralised spirometry
may include provision of the same spirometry equip-
ment to all study sites, consistent training of staff whomake spirometry assessments and calibration of equip-
ment daily.
Designing clinical trials of inhaled medications in COPD
Tiotropium is a commonly used once-daily inhaled
bronchodilator for the maintenance treatment of
patients with COPD and is a key comparator in evalu-
ation of new bronchodilators. However, the use of tiotro-
pium as a comparator presents several difficulties.
Firstly, tiotropium is a hygroscopic powder and cannot
be removed from the commercial capsules for repack-
aging into unmarked capsules. Secondly, the commer-
cially available capsules are marked with a logo that can
be seen through a window in the inhaler, making it im-
possible to completely mask the nature of the treatment,
and for legal reasons the logo/text cannot be copied
onto placebo capsules. The manufacture of tiotropium is
also difficult, particularly as the drug is very unstable in
the ambient air.
To overcome the problems associated with blinding, a
clinical trial of a treatment administered via a dry pow-
der inhaler (DPI) requires considerable resources and
possibly assistance from the manufacturer of the com-
parator DPI to create blinded commercial and placebo
products. Ultimately, an alternative clinical trial design
may need to be used.
Experience from the indacaterol clinical trial programme
Three Phase III clinical studies have compared indaca-
terol with tiotropium. As blinded tiotropium was not
available, alternative blinding methods were used
(Table 1). The INHANCE study was performed in two
stages in an adaptive seamless design [9]. In stage 1,
patients were randomised to receive double-blind inda-
caterol 75, 150, 300, or 600 μg once daily, double-blind
formoterol 12 μg twice daily, double-blind placebo, or
open-label tiotropium 18 μg once daily for 2 weeks. In
stage 2, patients continued treatment with two selected
doses of indacaterol (150 or 300 μg, based on 2-week ef-
ficacy and safety data), tiotropium, or placebo for 26
weeks, with additional patients recruited and rando-
mised. The INTIME study was a randomised, double-
blind, crossover study in which patients received three
of the following four treatments, each once-daily for 14
days and each followed by a 14-day washout: double-
blind indacaterol 150 or 300 μg, double-blind placebo or
third-party blind tiotropium [10]. The blinding of tiotro-
pium treatment was maintained by using a third-party
blinding procedure where the study drug was prepared
and provided to the patient by persons who were inde-
pendent of the other clinical trial processes (described in
more detail in Table 1). In the 12-week INTENSITY
study, a blinded, double-dummy design was used [11].
Following a 2-week run-in, patients were randomised to
Table 1 Description of indacaterol studies using a tiotropium comparator arm*
Study Description Design Blinding technique and reason Patient entry criteria Study duration Objectives
INHANCE [9]
Randomised, double-blind,
placebo-controlled study
assessing efficacy, safety
and tolerability of two
doses of indacaterol in
patients with COPD
using open-label tiotropium
as active control
Double-blind indacaterol
and placebo via
Breezhaler
W
.
Open-label tiotropium
via HandiHaler
W
No placebo to
tiotropium was available.*
Tiotropium was
administered open-label
FEV1 <80 and ≥30%
predicted FEV1/FVC <70%.
Smoking history ≥20
pack-years
26 weeks First objective:
superiority of
indacaterol to
placebo using
trough FEV1 at
12 weeks. Second
objective:
non-inferiority
of indacaterol to
tiotropium
using trough
FEV1 at 12 weeks
INTIME [10] Randomised, blinded,
placebo-controlled,
multicentre, three-period,
incomplete block,
multi-dose crossover
study to determine
the effect on lung function
of indacaterol in patients
with moderate-to-severe
COPD, using tiotropium
as an active control
Double-blind indacaterol
and placebo via Breezhaler
W
.
Third-party blinding of
tiotropium (via HandiHaler
W)†
Indacaterol and its matching placebo
were made identical in appearance
and were dispensed in such a manner
to make them indistinguishable
to patients and all blinded study personnel.
An exact physical match to tiotropium
was not available. Blinding of
tiotropium was maintained by use
of third-party blinding procedures†
FEV1 <80 and ≥30%
predicted FEV1/FVC <70%.
Smoking history ≥10
pack-years
70 days (14 days
treatment with four
different treatments
in three separate
periods with a
washout of 14
days between
treatments)
First objective:
superiority of
indacaterol to
placebo using
trough FEV1 at
14 days. Second
objective:
non-inferiority of
indacaterol to
tiotropium using
trough FEV1 at
14 days
INTENSITY [11] Randomised, parallel-group,
blinded, double-dummy
study to compare the
efficacy and safety of
indacaterol delivered via a
SDDPI with tiotropium
delivered via a HandiHaler
W
in patients with
moderate-to-severe COPD
Blind, double-dummy
indacaterol via Breezhaler
W
versus tiotropium
via HandiHaler
W
Patients receiving indacaterol also took
placebo via the inhaler used for tiotropium,
and patients receiving tiotropium took
placebo via the inhaler used for indacaterol.
The colour of the capsules was compatible, but
the placebo did not have the markings. The
blinding of tiotropium was maintained
by use of an unblinded individual, who was
not involved in any study assessments, to
administer treatment. Patients and
investigators therefore remained blind to
treatment allocation
FEV1 <80 and ≥30%
predicted FEV1/FVC <70%.
Smoking history ≥10
pack-years
12 weeks First objective:
non-inferiority of
indacaterol to
tiotropium using
trough FEV1 at
12 weeks Second
objective: superiority
of indacaterol to
tiotropium using
trough FEV1 at
12 weeks
*The blinding of tiotropium is complicated by the fact that patients place a capsule in the inhalation device (HandiHalerW) and are able to see the logo on the capsule through a window in the device. Neither placebo
tiotropium capsules with such a logo nor active tiotropium capsules without such a logo could be obtained for use in these studies of indacaterol; therefore, it was not possible to conduct traditionally designed
double-blind studies.
†Study drug was prepared and provided to the patient each morning, either at home or in the clinic by persons who were independent of the other clinical trial processes (referred to as ‘independent study blinding
co-ordinators’, ISBCs) to preserve the integrity of the blind. Two ISBCs were required for each daily study drug administration to each patient. The first (non-blinded) ISBC (who had no contact with the patient)
prepared the study drugs and devices. The second (blinded) ISBC provided the patient with the prepared study drug and devices, monitored administration of the drug by patients and ensured that the blinding was
maintained throughout. Both ISBCs completed the third-party blinding log for every drug administration, to provide evidence that the blinding procedure was strictly followed.
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; SDDPI: single dose dry powder inhaler.
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Table 2 Key results from indacaterol studies with a tiotropium comparator arm and double-blind studies with
tiotropium as the primary treatment of interest
Study Design Patient characteristics Time Trough FEV1 versus
placebo (mL)
Proportion of patients
achieving MCID
SGRQ (%) TDI (%)
Indacaterol versus tiotropium studies
INHANCE [9] OL* FEV1 <80% and ≥30% predicted;
FEV1/FVC <0.7; Mean FEV1 % predicted
}:
Indacaterol 150 μg 56.1, Indacaterol
300 μg 56.3, Tiotropium 53.9,
Placebo 56.1
12 wk Tiotropium: 140 44.9† 55.0†
Indacaterol 150 μg: 180 51.9† 58.9†
Indacaterol 300 μg: 180 50.1† 65.8†
26 wk Tiotropium: 140 47.3 57.3
Indacaterol 150 μg: 160 57.8 62.4
Indacaterol 300 μg: 180 52.5 70.8
INTIME [10] TPB FEV1 <80 and ≥30% predicted;
FEV1/FVC <0.7; Mean FEV1 % predicted
} 56.7
2 wk Tiotropium: 120 — —
Indacaterol 150 μg: 170 — —
Indacaterol 300 μg: 150 — —
INTENSITY [11] B FEV1 <80 and ≥30% predicted;
FEV1/FVC <0.7; Mean FEV1 % predicted
}:
Indacaterol 54.6, Tiotropium 54.3
12 wk Tiotropium: — 42.5 50.1
Indacaterol 150 μg 50.5 57.9
Tiotropium versus placebo studies
Beeh et al. 2006 [15] DB FEV1 ≤70% predicted; FEV1/FVC <0.7
{;
Mean FEV1 % predicted
{: Total 45.4,
Tiotropium 45.3, Placebo 45.7
12 wk 79 — —
Freeman et al. 2007 [16] DB FEV1 30–65% predicted; FEV1/FVC <0.7
};
Mean FEV1 % predicted
{: Total 48.9,
Tiotropium 47.9, Placebo 49.9
12 wk 60 — —
Johansson et al. 2008 [17] DB FEV1 >60% predicted; FEV1/FVC <0.7
};
Mean FEV1 % predicted
}:
Tiotropium 73.6, Placebo 73.2
12 wk 118 — —
Moita et al. 2008 [18] DB FEV1 ≤70% predicted; FEV1/FVC <0.7
{;
Mean FEV1 % predicted
{: Tiotropium:
non-smokers 38.4, smokers 44.4;
Placebo: non-smokers 42.3,
smokers 40.4
12 wk 102 — —
Verkindre et al. 2006 [19] DB FEV1 ≤50% predicted; FEV1/SVC
≤0.7; lung hyperinflation{; Mean FEV1 %
predicted{: Tiotropium 34.7,
Placebo 35.8
12 wk 110 59 —
Niewoehner et al. 2005 [20] DB FEV1 ≤60% predicted; FEV1/FVC <0.7
{;
Mean FEV1 % predicted
{: Tiotropium 35.6,
Placebo 35.6
13 wk 100 — —
26 wk 100 — —
Brusasco et al. 2003 [21] DB FEV1 ≤65% predicted; FEV1/FVC <0.7
{;
Mean FEV1 % predicted
{: Tiotropium 39.2,
Placebo 38.7
26 wk 120 48.9 43.1
Tonnel et al. 2008 [22] DB FEV1 20–70% predicted; FEV1/FVC 0.7
#;
Mean FEV1 % predicted
{: Tiotropium 47.5,
Placebo 46.2
12 wk — 60|| —
26 wk — 60|| —
39 wk 100 59.1 —
Chan et al. 2007 [23] DB FEV1 ≤65% predicted; FEV1/FVC <0.7
{;
Mean FEV1 % predicted
{: Tiotropium 39.4,
Placebo 39.3
11 wk 100|| — —
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Table 2 Key results from indacaterol studies with a tiotropium comparator arm and double-blind studies with
tiotropium as the primary treatment of interest (Continued)
48 wk 100 53 —
Casaburi et al. 2002 [24] DB FEV1 ≤65% predicted; FEV1/FVC <0.7
{;
Mean FEV1 % predicted
{: Tiotropium 39.1,
Placebo 38.1
13 wk 148|| — 42–47
25 wk 148|| — 42–47
1 yr 150|| 49 47
Tashkin et al. 2008 [25] DB FEV1 ≤70% predicted; FEV1/FVC <0.7
};
Mean FEV1 % predicted
}: Tiotropium 47.7,
Placebo 47.4
26 wk 100|| — —
4 yr 87–103 45% —
Data are least square mean for INHANCE, INTIME and INTENSITY; other publications did not describe the type of mean.
*Tiotropium arm (indacaterol and placebo were DB).
†Data on file at Novartis.
{Not stated whether pre- or post-bronchodilator.
}Pre-bronchodilator.
}Post-bronchodilator.
#Pre- and post-bronchodilator.
||Estimated from a figure.
Values are given as 42–47% across all timepoints up to 2 years (greatest improvement versus baseline was seen at 2 years).
Definitions of trough FEV1 varied (mean of 23 hours 10 minutes and 23 hours 45 minutes post-dose for INHANCE, INTIME and INTENSITY, Beeh et al. 2006 [15],
Verkindre et al. 2006 [19] and Brusasco et al. 2003 [21]; 10 minutes pre-dose for Freeman et al. 2007 [16], Johansson et al. 2008 [17] and Chan et al. 2007 [23]; 30
minutes pre-dose for Tonnel et al. 2008 [22]; 1 hour pre-dose for Casaburi et al. 2002 [24]; and ‘pre-dose’ for Niewoehner et al. 2005 [20] and Tashkin et al. 2008
[25]. All studies recruited patients aged ≥40 years with a smoking history of ≥10 pack-years (≥20 years for INHANCE).
MCID: minimum clinically important difference; SGRQ: St. George’s Respiratory Questionnaire; TDI: transition dyspnoea index; OL: open-label; FEV1: forced
expiratory volume in 1 second; FVC: forced vital capacity; TPB: third-party blinding; B: blinded; DB: double-blind; SVC: slow vital capacity.
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each once-daily for 12 weeks. Patients receiving indaca-
terol also took a placebo via the inhaler used for tiotro-
pium, and patients receiving tiotropium took a placebo
via the inhaler used for indacaterol. Blinding was
achieved by specifying that study medications were dis-
pensed by a third party not involved in other aspects of
the study. In all three studies, indacaterol was adminis-
tered via the BreezhalerW DPI device and tiotropium via
the HandihalerW DPI device.
Patient populations were similar across the three stud-
ies, which enrolled patients with moderate-to-severe
COPD (forced expiratory volume in 1 second [FEV1]
<80% and ≥30% predicted; FEV1/forced vital capacity
[FVC] <0.7) [12-14], and a smoking history of ≥10 pack-
years (INTIME and INTENSITY [10,11]) or ≥20 pack-
years (INHANCE [9]). The primary endpoint was trough
FEV1 (an objective endpoint) in all three studies, with
the primary comparisons being indacaterol versus pla-
cebo at Week 12 in INHANCE [9], Week 2 in INTIME
[10] and indacaterol versus tiotropium at Week 12 in
INTENSITY [11].
Effect of study blinding on objective measures: lung
function
The results of 24-hours post-dose (trough) FEV1 for ac-
tive treatment versus placebo in the INHANCE and
INTIME studies are shown in Table 2. The treatment
differences for tiotropium versus placebo were similar
across both studies, even though they differed inblinding of the tiotropium arm [9,10]. Treatment differ-
ences for indacaterol versus placebo were also consistent
across both studies.
Table 2 also shows FEV1 data from previous studies in
which tiotropium was the primary treatment of interest.
It should be noted that there were differences in entry
criteria and in definitions of trough FEV1 between
studies.
In the INHANCE study, the difference in trough FEV1
between open-label tiotropium and placebo was 140 mL
at both Weeks 12 and 26 [9]. These values are similar to
those recorded during the previous double-blind studies
of tiotropium at 12 weeks (60–148 mL), 26 weeks (100–
148 mL) and over the longer term (100–150 mL; Table 2
and Figure 1).
These findings suggest that there was no bias against
tiotropium for FEV1 in the open-label INHANCE study.
The 140 mL difference between tiotropium and placebo
in the indacaterol studies was greater than the differ-
ences seen at 12 and 26 weeks in the majority of the
double-blind studies of tiotropium, raising the possibility
that the bias, if any, was favouring the performance of
tiotropium (Figure 1). However, the variation in FEV1
even between the previous double-blind studies may
partly reflect differences in enrolment criteria, such as
COPD severity or patient characteristics.
In the INTENSITY study, which did not include a pla-
cebo arm, trough FEV1 at Week 12 was similar with
indacaterol (144 mL) and tiotropium (143 mL), and
non-inferiority was demonstrated [11]. Mean changes
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indacaterol (130 mL) and tiotropium (120 mL) in that
study.
Effect of study blinding on subjective measures: health-
related quality of life
As well as FEV1, many regulatory authorities recom-
mend that clinical trials in COPD include an endpoint
that reflects clinical benefit of treatment using a vali-
dated measure, such as the St. George’s Respiratory
Questionnaire (SGRQ) [26,27].
The SGRQ is used to assess health status in patients
with chronic respiratory disease and was included as a
measure in the INHANCE and INTENSITY studies. The
questionnaire, which is completed by the patient, com-
prises of 50 questions in three domains: symptoms, ac-
tivity (limitations) and impacts (of disease), which are
calculated to provide a score between 0 (best) and 100
(worst). The minimal clinically important difference
(MCID) for SGRQ score that is generally accepted as in-
dicating an improvement over placebo or from baseline
is −4 units [28].
After 12 weeks of treatment, the MCID for change in
SGRQ from baseline was achieved by 44.9% of
tiotropium-treated patients (with a mean improvement
of −1.1 units) in the INHANCE study (open-label tio-
tropium) and 42.5% of patients (with a mean improve-
ment of −3.0 units) in the INTENSITY study (blinded
tiotropium) [11,29] (Table 2). These values are slightly
lower than those recorded at 12 weeks in studies where
tiotropium was the primary treatment of interest
(Figure 2).Figure 1 Differences in trough forced expiratory volume in 1 second
studies in which tiotropium was the primary treatment of investigatio
at 11, 12 and 13 weeks; †Includes assessments made at 25 weeks; {Estimate
available.At 26 weeks, 47.3% of tiotropium-treated patients in
INHANCE achieved the MCID for change in SGRQ
(with a mean improvement of −1.0 units) compared with
a range of 49–60% in published tiotropium studies.
Overall, the percentage of patients treated with open-
label tiotropium in INHANCE who achieved the MCID
for change in SGRQ at 12 and 26 weeks, were within the
range of values recorded across all of the double-blind
tiotropium studies over the durations of 12 weeks to 4
years (Table 2 and Figure 2). Again, it should be noted
that, even in double-blind studies of tiotropium, there
was variability in the proportion of patients who
achieved the MCID for SGRQ (and in the mean im-
provement scores; –2.7 to −6.5).
These findings indicate that minimal bias was intro-
duced with the open-label design of the tiotropium com-
parator arm in the INHANCE study.
Dyspnoea – transition dyspnoea index (TDI)
Dyspnoea, or breathlessness, is the major limiting symp-
tom for COPD patients and is often measured using the
TDI [30], a tool recommended by regulatory authorities
for inclusion in clinical trials of treatments for COPD
[26].
The TDI is a multidimensional instrument that mea-
sures change from the baseline dyspnoea index (BDI)
over time [31]. The BDI considers three components
(functional impairment, magnitude of task and magni-
tude of effort), each rated from 0 (severe dyspnoea) to 4
(no dyspnoea). The TDI measures changes from baseline
in each domain of the BDI on a scale of +3 (major im-
provement) to −3 (major deterioration) and has been(FEV1) between tiotropium and placebo in INHANCE [9] and
n. Values are means and standard errors. *Includes assessments made
d from a figure (no standard error available); #No standard error
Figure 2 Percentages of tiotropium-treated patients achieving the minimum clinically important difference (MCID) for St. George’s
Respiratory Questionnaire (SGRQ) score in INHANCE [29], INTENSITY [11] and other studies in which tiotropium was the primary
treatment of investigation.
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MCID for the TDI is an improvement from the BDI
score of ≥1 unit [33].
The proportion of patients achieving an improvement
in TDI equal or greater to the MCID was assessed in the
INHANCE and INTENSITY trials of indacaterol
(Table 2). In the INHANCE study (open-label tiotro-
pium), the MCID for TDI was achieved by 55.0% of
tiotropium-treated patients at 12 weeks (with a mean
improvement of 0.75 points) and 57.3% at 26 weeks
(with a mean improvement of 0.87 points) [9], while in
the INTENSITY study (blinded tiotropium), 50.1% of
tiotropium-treated patients achieved the MCID at 12
weeks (with a mean improvement of 1.43 points) [11].
These values are slightly higher than the values recorded
during the previous studies of tiotropium [21,24], again
demonstrating that the open-label design of INHANCE
did not result in a bias against tiotropium (mean im-
provement of 0.8–1.28 points) (Table 2 and Figure 3).
Adverse events
In the INHANCE study, the overall incidence of adverse
events and the most commonly occurring adverse events
were similar across the treatment groups (indacaterol
150 or 300 μg, tiotropium, or placebo) [9]. Respiratory
tract infections and respiratory events were the most
common type of adverse events, serious events, and
those leading to withdrawal of study treatment. In the
INTIME study, the overall incidence of adverse events
was similar across all treatments (indacaterol 150 or 300
μg, tiotropium or placebo), and these were predomin-
antly mild or moderate in severity [10]. The mostfrequent adverse events were cough, COPD exacerba-
tion, and nasopharyngitis. In the INTENSITY study, ad-
verse events were reported for similar proportions of
patients in the two treatment groups (indacaterol and
tiotropium), with the most common events generally
reflecting the typical disease characteristics of COPD
[11]. These results reflect adverse events observed in
previous double-blind trials of tiotropium compared
with placebo [17,18,22,24,25].Additional evidence on the effect of study blinding on
treatment effect
It is worth noting that the third-party blinding proced-
ure used in the INTIME study required administration
of the study drug to the patient by a blinded individual,
and therefore the forced high compliance may poten-
tially bias results over what might be seen in a more
traditional clinical trial. In addition, the high manpower
intensity required for third-party blinding may limit
these studies to short periods of time.
Previous reports on the effects of blinding in RCTs
have been conflicting. Several studies examining the
effects of differing blinding techniques in RCTs from a
range of therapy areas have found that open-label stud-
ies tend to exaggerate the benefits of treatment when
they are included in meta-analyses [34-37]. For example,
Schulz et al. found that in open-label RCTs, odds ratios
were exaggerated by 17% [34]. Other studies of RCT
blinding have found that an open-label trial design is not
associated with treatment bias [38-40]. Moreover, inves-
tigations have shown that the adequacy of randomisation
Figure 3 Percentages of tiotropium-treated patients achieving the minimum clinically important difference (MCID) for transition
dyspnoea index (TDI) in INHANCE [9], INTENSITY [11] and other studies in which tiotropium was the primary treatment of
investigation. *Includes assessments made at 13 weeks; †Includes assessments made at 25 weeks; {Precise value is not given (values stated as
range of 42–47% across all timepoints).
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[39].
Observational studies are considered inherently biased
as they are both open-label and non-randomised [41,42].
However, a comparison of treatment bias in observa-
tional studies versus RCTs found that in 17 out of 19
analyses, the estimates of treatment effects from obser-
vational studies were similar to those from RCTs; in only
two of the 19 analyses did the combined magnitude of
the treatment effect in the observational studies lie out-
side the 95% confidence interval for the combined mag-
nitude in the RCTs [43]. Data from epidemiological
studies, while very different in design and quality from a
RCT indicate that objective outcomes are less affected
by bias associated with an open-label study design than
subjective outcomes [44]. Thus, even under conditions
where bias is expected, an open-label study design need
not introduce bias, particularly if assessments are based
on objective measurements.
Conclusions
Double-blind RCTs remain the gold standard for evalu-
ating interventions in chronic diseases such as COPD.
However, many drugs in COPD, particularly bronchodi-
lators, have an acute effect on both subjective and ob-
jective outcomes, therefore full blinding cannot be
guaranteed. If an open-label design is chosen, the poten-
tial for bias must be taken into account and the selection
of outcome measures is of pivotal importance. Measures
such as airway function are considered objective and less
prone to bias, and are therefore recommended as pri-
mary endpoints. Despite possible limitations associatedwith functional endpoints such as FEV1 in COPD, these
variables have proven reliable, are subject to little or no
placebo effect, and have produced consistent results that
are largely independent of study population, treatment
duration and differences in study design and blinding.
This low likelihood of bias with objective measures
of airway function is also supported by the fact that
spirometry has rigorous standards for performance in
clinical trials; any incomplete effort that can introduce
bias is detected by the technician/central agency and
not included. Thus, selection of an objective outcome
measure such as FEV1 in an open-label study in
COPD is unlikely to introduce relevant bias if tech-
nical requirements are met and established guidelines
are followed [45].
While this holds true for FEV1 and, potentially, other
objective endpoints in COPD, the inclusion of more sub-
jective, patient-reported outcomes may pose a larger
challenge. However, data from studies comparing inda-
caterol with tiotropium demonstrate that the effects of
tiotropium on subjective measures (SGRQ; TDI) vary
slightly across blinded and non-blinded studies, indicat-
ing that minimal bias was introduced by using open-
label tiotropium. It is likely that the appropriate use of
randomisation in the comparative studies was an im-
portant factor in minimising potential bias. Nevertheless,
the extent to which instruments such as symptom indi-
ces or health status questionnaires are affected by blind-
ing issues in the absence of a placebo control, are as yet
poorly characterised or unknown. Minimum clinically
important differences for these instruments have been
established using well-controlled, blinded trials against a
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pretation of data generated in open-label studies. As
more open-label data on these outcomes become avail-
able in the future, this may help to clarify the clinical
significance of treatment-associated changes observed in
the open-label studies discussed above.
In conclusion, when reporting a clinical trial, it is im-
portant to be transparent about who exactly was blinded
and how. If an open-label design is necessary, additional
efforts should be made to minimise the risk of bias. If
these recommendations are followed, and the data are
considered in the full knowledge of any potential sources
of bias, results with tiotropium suggest that data from
open-label studies can provide valuable and credible evi-
dence of the effects of a therapy.
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